
A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Keywords: کارآزمایی بالینی; DLBCL; Syk inhibitor; B-cell receptor; Phase II; Clinical trial;